Search Results 601-610 of 17852 for Coagulation

1. Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant - Mayo Clinic

   History of clinically significant bleeding or known platelet or coagulation disorder; Clinically significant cardiac illness including New York Heart ...

2. A Study to Evaluate M7824 with Concurrent Chemoradiation (cCRT) in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) - Mayo Clinic

   Adequate coagulation function defined as international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN unless the participant is receiving ...

3. Extracorporeal membrane oxygenation (ECMO) - Mayo Clinic

   In extracorporeal membrane oxygenation (ECMO), blood is pumped outside of the body to a heart-lung machine. The machine removes carbon dioxide and sends oxygen- ...

4. Pharmacokinetic and Safety Study of Nab ®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects with Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubenemia - Mayo Clinic

   Subject has acceptable coagulation studies (obtained ≤ 14 days prior to starting Cycle 1 Day 1) partial thromboplastin time (PTT) < 1.2 x ULN and INR ≤ 1.5 x ...

5. Safety Study of SEA-CD40 in Cancer Patients - Mayo Clinic

   Coagulation: International normalized ratio (INR) or prothrombin time (PT) ≤1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or ...

6. Phase 2b Study of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis - Mayo Clinic

   Presence of other clinically significant risk of bleeding events, including coagulation or platelet disorders, at the Screening Visit as determined by the ...

7. A Study to Assess Dendritic Cell Immunotherapy Plus Standard-of-Care to Treat Advanced Renal Cell Carcinoma - Mayo Clinic

   Adequate coagulation function as defined by either of the following criteria: 1. INR < 1.5 x ULN 2. For subjects receiving warfarin or LMWH, the subjects ...

8. Radiation Therapy with Durvalumab or Cetuximab to Treat Patients with Locoregionally Advanced Head and Neck Cancer who Cannot Take Cisplatin - Mayo Clinic

   Clinically apparent jaundice and/or known coagulation defects; Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel ...

9. Meet The Faculty - Abdominal Transplant Surgery Fellowship (Arizona) - Mayo Clinic College of Medicine & Science

   Liver, kidney, and pancreas transplantation; Hepatobiliary malignancy; Living donor transplant; Extended criteria organ donation; Thrombosis and coagulation ...

10. Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

    Has safety laboratory parameters (chemistry, hematology, coagulation, and urinalysis) outside normal limits (according to the central laboratory reference ...